Common use of Termination for a RBNC Distracting Product Clause in Contracts

Termination for a RBNC Distracting Product. AMGEN will have the right to terminate this Agreement in full upon written notice to RBNC in the event that RBNC (or its Sublicensee) violates Section 5.4.1 (Distracting Programs) (and, for clarity, does not comply with Sections 5.4.2, 5.4.3 or 5.4.4 as may be applicable). Notwithstanding the foregoing, in the case of a Sublicensee’s violation of Section 5.4.1 (Distracting Programs), if RBNC terminates the applicable Sublicense Agreement (or the portions of such Sublicense Agreement relating specifically to the Product if such Sublicense Agreement covers other programs or products) and regains all rights granted by it to such Sublicensee in the Products and Licensed Know -How within forty-five (45) days of becoming aware of Sublicensee’s violation of Section 5.4.1 (Distracting Programs), AMGEN will have no right to terminate this Agreement under this Section 9.2.2 with respect to such violation by such Sublicensee.

Appears in 4 contracts

Samples: Exclusive License Agreement (Neumora Therapeutics, Inc.), Exclusive License Agreement (Neumora Therapeutics, Inc.), Exclusive License Agreement (Neumora Therapeutics, Inc.)

AutoNDA by SimpleDocs
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!